top of page

Scientific conclusions and grounds for the variation to the terms of the marketing authorisations

Taking into account the PRAC Assessment Report on the PSUR(s) for empagliflozin, empagliflozin / metformin, the scientific conclusions of CHMP are as follows: A cumulative review was submitted with this PSUR regarding the important potential risk “Renal impairment”.

Click on this link for more information.


Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page